INTRODUCTION {#s1}
============

G protein-coupled receptors (GPCRs), the largest superfamily of receptors, are involved in a wide variety of biological functions \[[@R1]\], and their dysfunction contributes to many human diseases \[[@R2]\]. Increasing evidence indicates that aberrant GPCR signaling is implicated in cancer initiation and progression \[[@R3]--[@R5]\], and therefore the search for new GPCRs involved in these processes has become a strategy for the development of new cancer treatments. GPR55 is a GPCR that is engaged by lipids, specifically lysophosphatidylinositol (LPI) and certain cannabinoid compounds \[[@R6]--[@R8]\]. However, due to the lack of proof for *in vivo* activation by these ligands, this receptor remains in the Class A orphan subfamily \[[@R9]\]. Increasing evidence supports that GPR55 is an important component of the molecular circuitry that controls cancer cell behavior. Thus, this receptor has been shown to drive cancer cell proliferation in *in vitro* and/or *in vivo* models of glioblastoma \[[@R10]\]; prostate \[[@R11]\], ovarian \[[@R11]\] and skin carcinoma \[[@R12]\]; melanoma \[[@R13]\], and non-small lung cancer \[[@R14]\]. GPR55 has also been indirectly associated to both pro-angiogenic responses \[[@R15]\] and to pro-migratory phenotypes in breast \[[@R16]\] and colon cancer cells \[[@R17]\]. However, little is known about the real impact of these effects on the metastatic process, the final and most lethal stage of cancer progression, as well as the molecular mechanisms governing those actions. Hence, here we aimed at shedding light on these two particular issues by focusing on breast cancer, one of the leading causes of death in women \[[@R18]\].

RESULTS {#s2}
=======

GPR55 expression correlates with triple-negative tumors and poor patient prognosis {#s2_1}
----------------------------------------------------------------------------------

To understand the role of GPR55 in the advanced stages of breast cancer progression, we first investigated whether there was an association between GPR55 levels and patient prognosis. We analyzed GPR55 protein expression in a tissue microarray (TMA) containing 483 breast human samples \[[@R19]\]. We found a strong correlation between high GPR55 expression and reduced disease-free survival (Figure [1A](#F1){ref-type="fig"}). To determine whether this association was also observed at the mRNA level, we analyzed the publically available TCGA microarray data set that contains molecular and clinical data from 825 breast cancer patients \[[@R20]\]. Women with high tumor GPR55 mRNA expression presented reduced overall survival than those with low GPR55 mRNA levels (Figure [1B](#F1){ref-type="fig"}). In an additional dataset containing 295 breast cancer samples \[[@R21]\], high GPR55 mRNA expression was associated with reduced metastasis-free survival (Figure [1C](#F1){ref-type="fig"}). Since breast cancer is a very heterogeneous disease, we studied whether GPR55 expression was associated to a specific molecular subtype. We found a strong association between GPR55 protein levels and triple-negative tumors (Figure [1D](#F1){ref-type="fig"}). Specifically, moderate or high GPR55 staining was found in 82% of them (Figure [1D](#F1){ref-type="fig"}). Likewise, GPR55 mRNA levels were elevated in basal tumors with respect to the other molecular subtypes of breast cancer (i.e. normal-like, luminal A or B, and HER2-enriched) in two datasets containing a total of 2557 human samples \[[@R20], [@R22]\] (Figures [1E and 1F](#F1){ref-type="fig"}), and in basal human breast cancer cell lines with respect to cell lines with other molecular features (Figure [1G](#F1){ref-type="fig"}). Together, these findings show that an elevated GPR55 expression is associated with the highly aggressive basal/triple-negative breast cancer subtype, higher probability to develop metastases, and therefore poor patient prognosis.

![GPR55 expression correlates with triple-negative tumors and poor patient prognosis\
(**A--C**) Kaplan-Meier curves for disease-free survival (A), overall survival (B), and metastasis-free survival (C). Data plotted in A correspond to the human breast tumor tissues with complete clinical information contained in the 483-sample tissue microarray generated at the University Hospital of Kiel and described in \[[@R19]\]. Cases were scored as 0 (no staining), 1 (weak staining), 2 (moderate staining), or 3 (high staining), for GPR55 expression. A representative image of each category is shown in (**D**) upper panel. Scale bar, 0.25 mm. Samples scoring 0 were grouped as "low GPR55 expression", and cases scoring 1-3 as "high GPR55 expression". Data plotted in (B and C) were obtained from the microarray data sets published by the TCGA network in \[[@R20]\] (B), and from the microarray data set published in \[[@R21]\] (C). In these two panels, samples were ranked by GPR55 mRNA expression, and the best cutoff was manually selected. Survival curves were statistically compared by the log-rank test. (D) Association between GPR55 expression (as determined by staining scoring) and the molecular features of the breast tumor samples included in the TMAs described in (A). The Pearson\'s chi-squared test was used for statistical analysis. (**E--G**) Relative GPR55 mRNA expression in the indicated breast cancer subtypes (E and F) or human breast cancer cell lines (G). Data in (E and F) were obtained from the same database as in (B) (for E), and from database in \[[@R22]\] (in F). \*\**p* \< 0.01 *vs.* the rest of the subgroups \[except Normal-like in (E)\], and *vs.* MDA-MB-231 cells in (G).](oncotarget-07-47565-g001){#F1}

GPR55 bestows pro-metastatic advantages to breast cancer cells *in vitro* and *in vivo* {#s2_2}
---------------------------------------------------------------------------------------

As high tumor aggressiveness is intimately related to the capability of cancer cell dissemination and the establishment of metastatic lesions, we next analyzed whether GPR55 bestows pro-metastatic properties to triple-negative breast cancer cells. First, we studied the role of GPR55 in cancer cell invasion, a pivotal event involved in the generation of metastases \[[@R23]\]. Triple-negative MDA-MB-231 breast cancer cells increased their invasive behavior when either FBS (Figure [2A](#F2){ref-type="fig"}) or LPI (Figure [2B](#F2){ref-type="fig"}) was used as chemoattractant. This effect was markedly reduced when GPR55 expression was knocked-down (Figures [2A--2C](#F2){ref-type="fig"}), and rescued upon GPR55 ectopic overexpression (Figures [2D--2F](#F2){ref-type="fig"}). The role of LPI as a positive directional cue for GPR55 expressing cells was substantiated by directional migration experiments. Thus, the migration towards LPI observed in MDA-MB-231 cells (Forward Migration Index = 0.117) was abolished by GPR55 knockdown (Forward Migration Index = −0.025, Figure [2G](#F2){ref-type="fig"}). Similar effects were observed in an animal model of lung metastasis. Mice injected with MDA-MB-231 cells expressing endogenous levels of GPR55 bore significantly more metastases when treated with LPI than when treated with vehicle (Figures [2H and 2I](#F2){ref-type="fig"}). Injection into the circulation of MDA-MB-231 cells with reduced GPR55 expression generated significantly less lung metastases than injection of control cells, and, in this case, LPI did not increase the number of metastatic lesions (Figures [2H and 2I](#F2){ref-type="fig"}). Moreover, the number of metastases augmented when the injected cells overexpressed GPR55 (Figures [2H and 2I](#F2){ref-type="fig"}). These observations show that activation of GPR55 bestows pro-metastatic features to breast cancer cells both *in vitro* and *in vivo*.

![GPR55 confers pro-metastatic advantages on breast cancer cells *in vitro* and *in vivo*\
(**A--F**) Cell invasion assays were performed with four different cell lines: MDA-MB-231 cells stably expressing a shRNA selectively targeting GPR55 (shGPR55) or a non-targeted shRNA (shC) (A--C), or shGPR55 cells stably expressing a GPR55 overexpression plasmid (shGPR55 + GPR55) or the corresponding empty vector (shGPR55 + pcDNA3) (D--F). Results are expressed as invasion fold increase towards 10% FBS or 0.5 μM LPI *vs.* shC (A and B) or shGPR55 + pcDNA3 (D and E) vehicle-treated cells, set at 1. (C and F) Relative GPR55 mRNA expression in GPR55 knocked-down (C) and GPR55 overexpressing cells (F). (**G**) Angular histograms of shC (left panel) and shGPR55 (right panel) cells migrating in response to a LPI gradient. (**H**) Representative images of the lung metastases generated by injection of the indicated luciferase expressing cell lines. (**I**) Quantification of the lung bioluminescence signal. \**p* \< 0.05; \*\**p* \< 0.01 *vs.* shC or shGPR55 + pcDNA3 vehicle-treated cells/animals. \#*p* \< 0.05; \#\#*p* \< 0.01 *vs.* shC or shGPR55 + pcDNA3 FBS- or LPI-treated cells/animals.](oncotarget-07-47565-g002){#F2}

GPR55-driven pro-invasive responses involve coupling to G~q/11~ and activation of RhoA {#s2_3}
--------------------------------------------------------------------------------------

The molecular mechanisms responsible for GPR55-driven pro-metastatic properties were then studied. First, we analyzed which heterotrimeric G protein GPR55 activates to mediate its actions. Previous reports had shown that this receptor couples to G~12/13~ \[[@R24]--[@R29]\] and G~q/11~ proteins \[[@R28]\] as its other closely related lysophospholipid receptors \[[@R30]\]. We therefore focused on these two families of G proteins, which are in fact intimately related to the regulation of cytoskeleton rearrangement, cell migration and invasion, and thus the generation of metastases \[[@R3]--[@R5]\]. By an antibody-capture \[^35^S\]GTPγS scintillation proximity assay (SPA) \[[@R31]\], we observed that LPI induced the coupling of GPR55 to G~q/11~ in MDA-MB-231 cells, an effect that was not observed in cells with reduced expression of the receptor and that was rescued in GPR55 overexpressing cells (Figure [3A](#F3){ref-type="fig"}, left). No coupling to G~12/13~ in response to LPI was observed in any of these cell lines (Figure [3A](#F3){ref-type="fig"}, right). The specific activation of G~q/11~ by GPR55 was further confirmed by the use of different chimeric constructs that behave as dominant-negative mutants for either G~q/11~ or G~12/13~. In this case, the increased invasiveness evoked by LPI in GPR55-overexpressing cells was prevented when G~q/11~ signaling was blocked by using a GFP-GRK2 chimeric construct (Figure [3B](#F3){ref-type="fig"}). In contrast, blockade of G~12/13~ signaling by means of a GFP-RGS chimera did not alter LPI-induced GPR55-mediated cancer cell invasion (Figure [3B](#F3){ref-type="fig"}). One of the main targets of G~q/11~ involved in actin remodeling, cell dynamics and metastasis is the Rho family of small GTPases, which consists of three subfamilies (Rho, Rac, and Cdc42) \[[@R5], [@R32]\]. GPR55 has been shown to activate Rho GTPases in non-cancer contexts \[[@R24], [@R26], [@R28], [@R29], [@R33], [@R34]\]. In our experimental setting, LPI significantly stimulated RhoA activity, and this effect was prevented by GPR55 knock-down (Figure [3C](#F3){ref-type="fig"}, left). In contrast, neither Rac1 (Figure [3C](#F3){ref-type="fig"}, middle) nor Cdc42 (Figure [3C](#F3){ref-type="fig"}, right) changed their activity upon LPI challenge (Figure [3C](#F3){ref-type="fig"}). Together, these findings support that GPR55 activation elicits pro-invasive responses in cancer cells by binding to G~q/11~ heterotrimeric G proteins and activating RhoA.

![GPR55-driven pro-invasive responses involve coupling to G~q/11~ and activation of RhoA\
(**A**) Activation of G~q/11~ or G~12/13~ proteins by LPI (10^−5^ M) as determined by Antibody-capture \[^35^S\]GTPγS scintillation proximity assay (SPA). Results are expressed as percentage of \[^35^S\]GTPγS basal binding (BB, binding obtained in the absence of the agonist, set as 100% for each cell line, and represented as a single bar in the graphs) to the indicated subunit. (**B**) Invasion of shGPR55 + GPR55 cells after incubation with 0.5 μM LPI or the corresponding vehicle (PBS) for 24 h, in the presence of a construct blocking G~q/11~ (GRK2) or G~12/13~ signaling (RGS), or the corresponding empty vector (GFP). (**C**) Activation of the indicated small GTPases after a 3 min incubation with 0.5 μM LPI. Results are expressed as fold increase activation over the corresponding vehicle-treated cells, set at 1. \**p* \< 0.05; \*\**p* \< 0.01 *vs.* vehicle-treated cells. \#\#*p* \< 0.01 *vs.* GFP LPI-treated cells. \#*p* \< 0.01 *vs.* LPI-treated cells.](oncotarget-07-47565-g003){#F3}

GPR55 activates the transcription factor ETV4/PEA3 through coupling to G~q/11~ and stimulation of ERK {#s2_4}
-----------------------------------------------------------------------------------------------------

To further characterize the downstream molecular players responsible for GPR55-driven pro-metastatic features, we analyzed the expression of a series of metastasis-related genes in response to LPI. By using a Human Metastasis PCR Array we found a group of genes that were modulated by LPI in GPR55-expressing cells ([Supplementary Table S1](#SD1){ref-type="supplementary-material"}). Among them, we focused our interest on those whose increased expression was ablated when GPR55 was silenced. One of them was the transcription factor ETV4/PEA3 (Figure [4A](#F4){ref-type="fig"}), which has been associated with metastasis in different tumor types \[[@R35], [@R36]\], including breast adenocarcinomas in general \[[@R37]\] and triple-negative breast cancers in particular \[[@R38]\]. First, we validated the reduction in ETV4 mRNA found after GPR55 stable knockdown by silencing the receptor transiently in MDA-MB-231 cells and an additional triple-negative breast cancer cell line (MDA-MB-468, Figure [4B](#F4){ref-type="fig"}), which ruled out the possibility that reduced ETV4 mRNA levels were a consequence of adaptive mechanisms to the chronic lack of GPR55 or a cell line-specific event. ETV4 mRNA expression was enhanced by LPI both in cell cultures (Figure [4A](#F4){ref-type="fig"}) and in the lung metastases generated in immunodeficient mice (Figure [4C](#F4){ref-type="fig"}), an effect that was not observed upon GPR55 knock-down (Figures [4A and 4C](#F4){ref-type="fig"}). Moreover, the increase in cell invasion produced by LPI was abolished by ETV4 transient knockdown (Figure [4D](#F4){ref-type="fig"}). In line with our previous data pointing to the involvement of G~q/11~ in LPI action, the increase in ETV4 levels produced by this GPR55 ligand was abrogated when G~q/11~ signaling was blocked with the GFP-GRK2 chimera (Figure [4E](#F4){ref-type="fig"}). It has been described that ETV4 expression is controlled by ERK in esophageal cancer \[[@R39]\] and so we found in our triple-negative breast cancer setting. Thus, LPI increased ERK phosphorylation (i.e. activation) via GPR55 (as demonstrated by the lack of such effect in GPR55 silenced cells; Figure [4F](#F4){ref-type="fig"}), and through the coupling to G~q/11~ (as demonstrated by the blockade of this action by the GFP-GRK2 construct; Figure [4G](#F4){ref-type="fig"}). Importantly, the increase in ETV4 mRNA levels induced by LPI was prevented by the inhibition of the ERK cascade with the MEK inhibitor U0126 (Figure [4H](#F4){ref-type="fig"}). Together, these results support that the prometastatic responses induced by GPR55 are mediated by the coupling to G~q/11~ and the subsequent activation of ERK, which in turn controls ETV4 expression.

![GPR55 activates the transcription factor ETV4/PEA3 through coupling to G~q/11~ and stimulation of ERK\
Relative ETV4 mRNA expression in the indicated cell lines (**A** and **B**), in the metastases derived from those cell lines (**C**) (see Figure [2G--2H](#F2){ref-type="fig"} for details on metastasis generation and treatment), and in shC cells transfected with constructs blocking blocking G~q/11~ (GRK2) or G~12/13~ signaling (RGS), or the corresponding empty vector (GFP) (E). In A, ETV4 expression was determined by the RT2 Profiler PCR Array of Human Tumor Metastases (see [Supplementary Table S1](#SD1){ref-type="supplementary-material"} legend), and in (B), (**C** and **E**) by real-time quantitative PCR. In (B), siGPR55 1 and 2 represent two different GPR55 siRNAs. (D) Invasion of the indicated cell lines upon transient ETV4 knockdown. (**F** and **G**) Western blot analysis of phospho-ERK in shC and shGPR55 cells after treatment with 0.5 μM LPI or the corresponding vehicle (PBS) for 3 min (F) and shC cells after incubation with LPI and expressing the indicated G protein signaling blocking constructs (G). Representative luminograms are shown. Numbers on top of the images correspond to the densitometric analysis of pERK levels and are expressed as fold increase *vs.* the corresponding vehicle-treated cells, set at 1 (*n* = 3). (**H**) Relative ETV4 mRNA expression, as determined by real-time quantitative PCR, in shC cells challenged with 0.5 μM LPI and the MEK inhibitor U0126 (1μM) for 3 min. \*\**p* \< 0.01 *vs.* siC or shC vehicle-treated cells. \#\#*p* \< 0.01 *vs.* siC or shC LPI-treated cells (C), GFP LPI-treated cells (E) or LPI-treated cells (H).](oncotarget-07-47565-g004){#F4}

DISCUSSION {#s3}
==========

Our results show that activation of GPR55 promotes metastasis in breast cancer, thus supporting that this receptor may be exploited as a new target in oncology, specifically in the metastatic disease associated to the highly aggressive triple-negative breast cancer. Indirect links between GPR55 and metastasis have been previously suggested in other cancer types. For example, Piñeiro *et al.* showed that anchorage-independent growth (a crucial feature of cancer cells during metastatic spreading) of a prostate cancer cell line was inhibited by GPR55 downregulation \[[@R11]\]. More recently, Kargl *et al.* have reported that pharmacological and genetic blockade of GPR55 impairs migration of a colon cancer cell line *in vitro* and in an animal model of liver metastasis \[[@R17]\]. Regarding breast cancer specifically, Ford *et al.* demonstrated that LPI induces migration and elongation of MDA-MB-231 cells \[[@R16]\]. However, in the latter study it remained unclear whether the LPI effects were mediated by GPR55. Ford *et al.* also observed that the poorly metastatic MCF-7 cell line (which expresses low levels of GPR55) increases its migration capacity upon GPR55 overexpression, an effect that was increased by LPI and completely blocked by selective GPR55 knockdown \[[@R16]\]. The work presented here cogently shows that activation of GPR55 promotes metastatic responses *in vitro* and *in vivo* in triple-negative breast cancer. These results suggest that blockade of this receptor may be a useful strategy for the management of the metastatic disease in this population. The pharmacology of GPR55 is still quite controversial and most compounds with activity on this receptor bind to additional targets. It would be therefore desirable to find/synthesize compounds with blocking activity selectively on GPR55 to test their actual therapeutic potential.

Our findings also show that GPR55 may have not only predictive but prognostic value. Thus, an elevated GPR55 expression is associated with the basal/triple-negative breast cancer subtype, higher probability to develop metastases, and therefore poor patient prognosis. This notion that the LPI/GPR55 axis may represent a new marker with prognostic value is supported by additional observations. Regarding GPR55 itself, our group has previously observed that this receptor is upregulated in human skin tumors and other human squamous cell carcinomas compared with the corresponding healthy tissues \[[@R19]\], and that high GPR55 expression correlates with high histological grade in breast, pancreas and brain tumors, as well as with decreased overall survival in glioblastoma patients \[[@R10]\]. Additionally, increased levels of the proposed endogenous GPR55 ligand LPI \[[@R40]\], have been found in plasma and/or ascites from patients with colon \[[@R17]\] or ovarian cancer \[[@R41], [@R42]\], when compared with healthy subjects, or with women with non-cancerous pathologies. It would be very interesting to conduct similar studies in larger cohorts of breast cancer patients, which should include samples from the different molecular subtypes, to determine whether the association between GPR55 expression and poor prognosis in triple-negative cases that we report here occurs concomitant with elevated LPI plasma levels.

MATERIALS AND METHODS {#s4}
=====================

Ethics statement {#s4_1}
----------------

Investigation has been conducted in accordance with the ethical standards and according to the Declaration of Helsinki, and according to national and international guidelines, and has been approved by the authors\' institutional review board.

Tissue microarrays (TMAs) {#s4_2}
-------------------------

PFA-fixed and paraffin-embedded blocks of tumor tissue from cases operated in the University Hospitals of Kiel between 1997 and 2010 were used for TMA construction. All patients gave informed consent, and the study was authorized by the Hospital\'s Ethics Committee. TMAs were generated by punching two 1 mm spots of each patient\'s sample. This resulted in a series of 483 tumor samples. Complete histopathological information was available for all the patients, including date and cause of death as well as date of local and/or distant relapse.

Immunohistological analysis {#s4_3}
---------------------------

Tissue sections were subjected to a heat-induced antigen retrieval step prior to exposure to an anti-GPR55 antibody (Abcam, Cambridge, UK). Immunodetection was performed using the Envision method with DAB as the chromogen. For GPR55 expression, cases were scored as 0 (no staining), 1 (weak staining), 2 (moderate staining), or 3 (high staining). Anti-GPR55 antibody specificity controls have been previously reported \[[@R12]\].

Real-time quantitative PCR, and analysis of published microarray datasets {#s4_4}
-------------------------------------------------------------------------

RNA was isolated with Trizol Reagent (Invitrogen, Barcelona, Spain) with the Real Star Kit (Durviz, Valencia, Spain), and cDNA was obtained with Transcriptor Reverse Transcriptase (Roche Applied Science, Barcelona, Spain). The primers used for GPR55 amplification were: sense 5′-CATGTGTTTCTCCAACGTCAA-3′ and antisense 5′-TGCGGAATTCTTTGATGACA-3′; and for ETV4 amplification: sense 5′-GCAGTTTGTTCCTGATTTCCA-3′ and antisense 5′-ACTCTGGGGCTCCTTCTTG-3′. Probes were from the Universal Probe Library (Roche Applied Science), and TATA Binding Protein (TBP) was used as reference: sense 5′-CCCATGACTCCCATGACC-3′ and antisense 5′-TTTACAACCAAGATTCACTGTGG-3′).

Human GPR55 mRNA expression was obtained from the microarray dataset published by the TCGA network in \[[@R20]\], downloaded from the cBio Cancer Genomics Portal \[[@R43]\]; from the microarray data set published in \[[@R21]\], downloaded from the Stanford Microarray Database (<http://microarray-pubs.stanford.edu/wound_NKI/explore.html>); and from database in \[[@R22]\], obtained through the European Genome-Phenome Archive (<http://www.ebi.ac.uk/ega/>) (accession number EGAS00000000083).

Cell cultures {#s4_5}
-------------

All the human breast adenocarcinoma cell lines were from ATCC-LGC (Barcelona, Spain). To stably knockdown GPR55 in MDA-MB-231 cells, a target-specific shRNA construct was used (GeneCopoeia, Rockville, MD). A scrambled shRNA construct was used as control (GeneCopoeia). Stably transfected cells were selected with puromycin. Transient GPR55 and ETV4 knockdown were carried out by using different ON-TARGETplus siRNAs (Dharmacon, Lafayette, CO): GPR55 siRNA1: 5′-GAAUUCCGCAUGAACAUCA-3′; GPR55 siRNA2: 5′-GAGAAACAGCUUUAUCGUA- 3′; for ETV4 a SMARTpool consisting of 4 different siRNAs was used: 5′-GGGCAGAGCAACGGAAUUU-3′, 5′-GAAU GGAGUUCAAGCUCAU-3′, 5′-GGACUUCGCCUAC GACUCA-3′ and 5′-GAUGAAAGCCGGAUACUUG- 3′. A non-targeted siRNA was used as control: 5′-UUCU CCGAACGUGUCACGUtt-3′. For the generation of MDA-MB-231 cells overexpressing GPR55, a 3xHA-GPR55 plasmid, or the corresponding empty vector (pcDNA3, Invitrogen) were used. All transfections were performed with Lipofectamine 2000 (Invitrogen). The graphs showing the resulting GPR55 or ETV4 mRNA levels are shown in [Supplementary Figure S1](#SD1){ref-type="supplementary-material"}. All cell lines were maintained in DMEM supplemented with 10% FBS.

The chimeric constructs to block G~q/11~ or G~12/13~ signaling were generated by fusion of a GFP containing pCEFL plasmid to the RGS domain of GRK2 (GFP-GRK2) or to the RGS domain of PDZ-RhoGFP (GFP-RGS) \[[@R44]\].

Cell invasion {#s4_6}
-------------

Cell invasion assays were performed in BD BioCoat^TM^ Matrigel^TM^ Invasion Chambers (BD Biosciences, Bedford, MA). Transwell inserts were placed onto 24-well, glass bottom greiner multiwell plates. Chemoattractants (10% FBS or 0.5 mM LPI) were added into the wells, and serum starved cells were placed into the inserts. After 24 h incubation, cells were fixed in 4% formaldehyde and stained with DAPI (Roche Pharma, Madrid, Spain). Images were taken with a confocal microscope (Leica TCS SP5) using a 20X DRY 0.7 NA objective. Capturing conditions were set up in two independent channels for DAPI stained cells and insert membrane reflection. Four equidistant non-overlapping fields were acquired close to the center of each insert avoiding possible influences from borders. For each field a volume big enough to contain all (migrating and non-migrating) cells was captured with a Z distance between images of 1 micron (small enough relative to nuclei size to make sure no nuclei was left unnoticed). All stack fields were visualized using Imaris x64 7.3.1 software. The center of every cell was recorded relative to the transwell insert membrane and cells were classified as either migrating or non migrating cells. Cells in touch with image borders were discarded.

Chemotaxis assays {#s4_7}
-----------------

2D chemotaxis μ-slide chambers (Ibidi, Munich, Germany) were precoated with collagen and cells where allowed to adhere and serum starve overnight. Incomplete media alone or supplemented with LPI (1 μM) were located in the reservoir chambers. Cell migration was imaged by time lapse microscopy (IX83 inverted microscope, Olympus; 20x magnification) at 5 minutes intervals over a period of up to 20 hours. Image J Manual Tracking plug-in and Chemotaxis Migration tool (Ibidi) were used to quantify the cell trajectories.

Generation of lung metastases {#s4_8}
-----------------------------

Lung metastases were generated by injection of the different luciferase expressing cell lines (5 × 10^5^) into the lateral tail vein of 6 week-old NOD/SCID female mice. Starting from day 2 after cell injection, half of the animals of each experimental group received LPI treatment (12 μg, i.p., three times per week) and the other half treatment with the corresponding vehicle (PBS). Forty five days after cell injection, animals were analyzed by bioluminescence after an intraperitoneal injection of D-Luciferin (Sigma) in an IVIS 2000 system (Xenogen Corp, Alameda, CA). Imaging data were processed with Living Image software (Xenogen Corp).

Antibody-capture \[^35^S\]GTPγS scintillation proximity assay (SPA) {#s4_9}
-------------------------------------------------------------------

SPAs were performed as previously described \[[@R45]\]. Briefly, cell membrane homogenates were incubated in 96-well Isoplates (Perkin Elmer Life Sciences, Maanstraat, Germany) in incubation buffer containing 0.4 nM \[^35^S\] GTP~γ~S (Perkin Elmer) and 50 or 100 μM GDP for G~q/11~ or G~12/13~ proteins, respectively. Specific antibodies for each G~α~ subunit (rabbit polyclonal anti-G~αq/11~ and rabbit polyclonal anti-G~α12/13~; Santa Cruz Biotechnologies, Madrid, Spain) and PVT SPA beads coated with protein A (Perkin Elmer) were used. Radioactivity was quantified on a MicroBeta TriLux scintillation counter (Perkin Elmer).

Activity of Rho family GTPases {#s4_10}
------------------------------

The activity of the Rho family of small GTPases was determined by RhoA/Rac1/Cdc42 Activation Assay Combo Biochem Kit™ (Cytoskeleton, Denver, CO) following manufacturer\'s instructions.

Human metastasis PCR array {#s4_11}
--------------------------

The expression of metastasis related genes after treatment with LPI (0, 5 μM, 20 h) or the corresponding vehicle (PBS) was determined by the RT2 Profiler PCR Array of Human Tumor Metastases (ref. 524 PAHS-028Z-4, Qiagen, Valencia, CA). RNA from cell cultures was isolated with Trizol reagent (Sigma, St. Louis, MO), including a DNA digestion step with genomic DNA elimination mix (Qiagen). cDNA was subsequently obtained with a RT2 first strand kit according to manufacturer\'s instructions (Qiagen). Real-time PCR assay was performed using the RT2 profiler PCR array in combination with RT2 SYBR Green master mix (Qiagen). Amplifications were run in a 7900 HT-fast real-time PCR system (Applied Biosystems, Carlsbard, CA), and data were analyzed using the SABiosciences PCR array data analysis template Excel (Qiagen).

Western blot analysis {#s4_12}
---------------------

Lysates from the different cell lines or lungs were obtained, and proteins were separated by SDS--PAGE and then transferred onto PVDF membranes. Blots were incubated with anti-phospho-ERK (Thr202/Tyr204), anti-ERK (Cell Signaling Technology, Danvers, MA, USA) and anti-α-Tubulin (TUB) (used as loading control, Sigma-Aldrich). Luminograms were obtained with the Amersham Enhanced Chemiluminescence Detection Kit (GE Healthcare, Uppsala, Sweden), and densitometric analysis was performed with Quantity One software (Bio-Rad, Madrid, Spain).

Statistical analysis {#s4_13}
--------------------

The Pearson\'s chi-squared test was used for the analysis of the association between GPR55 expression and the molecular features of the breast tumor samples included in the TMA. Kaplan-Meier survival curves were statistically compared by the log-rank test. Analysis of variance (ANOVA) with a post hoc analysis by the Student-Newman-Keuls\' test was routinely used for the rest of the analyses.

SUPPLEMENTARY MATERIALS {#s5}
=======================
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